The 2022 SOHO Annual Meeting kicked off with remarks from 2022-2023 President Moshe Talpaz, MD. In his President's Letter, Moshe Talpaz, MD, discusses all of the treatment progress made for hematologic malignancies. LAVA-051 consists of two single domain antibodies linked via a short five amino acid glycine-serine linker. The phase I/II study included patients with relapsed/refractory CLL or MCL who received two or more prior systemic therapies.